Trial reportBreast (Edinburgh, Scotland)2026
Efficacy of scalp cooling system versus chemical cooling cap in preventing chemotherapy-induced alopecia in breast cancer (COHAIR Study): a prospective randomized trial.
Trial report in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03711877 (Comparative Study of Scalp Cooling System and Chemical Cold Cap on Prevention of Chemotherapy-induced Alopecia in Women With Breast Cancer), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparative Study of Scalp Cooling System and Chemical Cold Cap on Prevention of Chemotherapy-induced Alopecia in Women With Breast Cancer
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionA prospective, randomized trial was conducted at a tertiary cancer hospital, to investigate the efficacy of scalp cooling system and chemical cooling cap in preventing chemotherapy-induced alopecia (CIA) in early breast cancer.
methodsPatients were randomly assigned to scalp cooling system group or chemical cooling cap group. Alopecia was assessed using the World Health Organization toxicity grading scale for anticancer drug and Quality of life and psychological status were evaluated using the European Organization for Research and Treatment of Cancer Quality of life Questionnaire Core 30 and the Hospital Anxiety and Depression Scale.
resultsA total of 152 patients were included in the random grouping process. The mean age of the participants was 44.6 ± 9.0 years (range 27-65 years), and 97.4% patients were diagnosed invasive ductal carcinoma. Among 117 patients completed the observation period with four cycles of anthracycline followed by four cycles of taxane regimen, hair preservation success rates were 74.5% in scalp cooling system and 71.2% in chemical cooling cap group and demonstrated good tolerability. The chemical group showed significantly lower anxiety scores and better QoL.
conclusionsCooling therapies effectively improved CIA. Scalp cooling showed superior early efficacy during anthracycline treatment, while chemical cooling provided better psychological outcomes and QoL benefits. Disease-free survival (DFS) was comparable between groups. CLINICAL
trial registrationNCT03711877 on 26 November 2021.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.